Company / Operating Cash Flow
Amgen Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$10.0B
FY2025
5-year range
$8.5B / $11.5B
FY2021-FY2025
Trend
-13.3%
vs FY2024
Sector context
#8 of 214
Health Care
What the data says
Among 214 Health Care companies, Amgen is in the top 4% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from $8.5B in FY2023 to $11.5B in FY2024.
Based on SEC 10-K filings.
$10.0B in FY2025 with a 5-year CAGR of -1.0%. Top quartile in the Health Care sector.
Improved from $8.5B to $10.0B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +0.8%
- 5-Year CAGR
- -1.0%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 214This company $10.0B Sector average $663.6M
▼
+1400.6% above sector average
Key checks
Key Insights
- 5-year CAGR of -1.0%, indicating a declining trend.
- In FY2025, operating cash flow decreased 13.3% year-over-year.
- Ranks #8 out of 214 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.0B | -13.3% |
| FY2024 | $11.5B | +35.6% |
| FY2023 | $8.5B | -12.9% |
| FY2022 | $9.7B | +5.0% |
| FY2021 | $9.3B | -11.8% |
| FY2020 | $10.5B | +14.7% |
| FY2019 | $9.2B | -19.0% |
| FY2018 | $11.3B | +1.1% |
| FY2017 | $11.2B | +7.9% |
| FY2016 | $10.4B | +6.4% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026